רווח למניה בשנים עשר החודשים האחרונים: Zentalis Pharma (ZNTL)

Zentalis Pharmaceuticals (ZNTL) relies on a stable staff of leading oncologists and chemists. Net income per share over the last 12 months demonstrates local dynamics, with the value holding at -1.92. The business is based on non-cyclical demand in breast cancer therapy, utilizing external CRO and CMO capacities to minimize operational risks during the development of new molecules.
פילוחים אנליטיים של חברת Zentalis Pharmaceuticals (ZNTL)

Net income per share (TTM) serves as a fundamental filter to separate the underlying trend from market noise. This metric normalizes the company's total income by the number of securities, allowing for a comparison of business efficiency against industry benchmarks. The current trailing twelve-month earnings per share value is -1.92. This figure reflects the financial stability of Zentalis Pharmaceuticals (ZNTL). The brand's high scientific authority in oncology therapy determines the long-term dynamics of this profitability.